Text Size

Identifying Factors Underlying the Discontinuation of Triptans

This study has been completed.
Sponsor:
Collaborator:
Merck
Information provided by (Responsible Party):
Todd J. Schwedt, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00890357
First received: April 27, 2009
Last updated: March 27, 2013
Last verified: March 2013
History of Changes
  Purpose

The objective of this study is to identify reasons migraine patients stop using triptan medications for abortive headache treatment. It is hypothesized that inadequate education of the patient at the time of prescribing the triptan is positively associated with triptan discontinuation.


Condition
Migraine
Medication Adherence

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Identifying Factors Underlying the Discontinuation of Triptans

Resource links provided by NLM:

MedlinePlus related topics: Headache Migraine
U.S. FDA Resources

Further study details as provided by Mayo Clinic:

Enrollment: 292
Study Start Date: August 2009
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Triptan User
Triptan Discontinued

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adult Specialty Headache Clinics

Criteria

Triptan User Inclusion Criteria:

  • Episodic Migraine or Chronic Migraine
  • Have used a triptan medication in the prior 3 months
  • Have used triptan medications for at least 1 year

Triptan Discontinuation Inclusion Criteria:

  • Episodic Migraine or Chronic Migraine
  • Used any triptan medication in the last 2 years
  • Have not used a triptan medication in the last 6 months
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00890357

Locations
United States, Florida
University of South Florida College of Medicine
Tampa, Florida, United States, 33612
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
Mayo Clinic
Merck
Investigators
Principal Investigator: Todd Schwedt, MD Mayo Clinic
  More Information

No publications provided

Responsible Party: Todd J. Schwedt, PI, Mayo Clinic
ClinicalTrials.gov Identifier: NCT00890357     History of Changes
Other Study ID Numbers: 09-0111
Study First Received: April 27, 2009
Last Updated: March 27, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
 Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on June 17, 2013